Ahren II is a venture capital fund established in 2022 and managed by Ahren Innovation Capital, which was founded in 2018 and is based in London, United Kingdom. The firm focuses on investing in transformational companies that operate at the intersection of deep technology and deep science, targeting sectors with significant market potential. Ahren Innovation Capital combines investment expertise with insights from leading scientists, fostering relationships built on trust to empower exceptional founders and teams. The firm takes a calculated approach to risk, aiming to provide both patient and active capital that supports innovative ventures poised for substantial growth.
Adrestia is developing therapeutics that work in an entirely new way – restoring the biological balance in damaged, diseased or dying cells
Adrestia Therapeutics
Seed Round in 2018
Adrestia is developing therapeutics that work in an entirely new way – restoring the biological balance in damaged, diseased or dying cells
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.